Plain-English translation of NCT07128355 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing whether and — two new medications that work by boosting your immune system — can work better when combined with focused radiation therapy aimed directly at liver tumors. The trial enrolls people with colorectal cancer that has spread to the liver and who have already tried standard chemotherapy without success. Researchers hope this combination approach will help control the cancer better than each treatment alone.
Many people with colorectal cancer that has spread to the liver have few treatment options after standard chemotherapy stops working. This medication represents a new way to fight cancer by jumpstarting the immune system, and early research suggests it might work especially well when combined with radiation therapy that damages cancer cells directly.
You likely qualify if…
You likely don't qualify if…
You would first receive focused radiation therapy to your liver tumors over 2–3 weeks. Then you would receive the two new medications: one as an infusion on the first day of each 6-week cycle, and the second as an infusion every 2 weeks. The medication phase lasts up to 24 weeks with both drugs, followed by an additional 14 cycles (about 84 weeks total) of one medication alone. You'll have regular clinic visits for blood tests, scans, and check-ins, and researchers will follow your health for a full year after treatment ends.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States